biote Corp. (NASDAQ:BTMD) Major Shareholder Guines Llc Acquires 436,037 Shares

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc acquired 436,037 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was purchased at an average cost of $3.26 per share, with a total value of $1,421,480.62. Following the completion of the acquisition, the insider now owns 4,611,071 shares of the company’s stock, valued at $15,032,091.46. The trade was a 10.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Guines Llc also recently made the following trade(s):

• On Wednesday, April 30th, Guines Llc purchased 1,933 shares of biote stock. The shares were purchased at an average cost of $3.30 per share, for a total transaction of $6,378.90.
• On Monday, April 21st, Guines Llc acquired 8,801 shares of biote stock. The stock was acquired at an average cost of $3.27 per share, with a total value of $28,779.27.
• On Thursday, April 17th, Guines Llc bought 6,874 shares of biote stock. The shares were acquired at an average cost of $3.29 per share, for a total transaction of $22,615.46.
• On Wednesday, April 9th, Guines Llc purchased 13,532 shares of biote stock. The stock was acquired at an average cost of $3.21 per share, with a total value of $43,437.72.
• On Monday, April 7th, Guines Llc bought 43,378 shares of biote stock. The stock was acquired at an average cost of $3.15 per share, for a total transaction of $136,640.70.
• On Thursday, April 3rd, Guines Llc bought 7,321 shares of biote stock. The shares were bought at an average cost of $3.24 per share, with a total value of $23,720.04.
• On Monday, March 31st, Guines Llc purchased 106,000 shares of biote stock. The stock was bought at an average cost of $3.32 per share, for a total transaction of $351,920.00.
• On Monday, March 17th, Guines Llc acquired 100 shares of biote stock. The shares were bought at an average price of $3.74 per share, with a total value of $374.00.
• On Thursday, March 13th, Guines Llc purchased 750,000 shares of biote stock. The shares were purchased at an average cost of $3.22 per share, with a total value of $2,415,000.00.

biote Trading Up 6.7 %

Shares of NASDAQ BTMD opened at $3.99 on Friday. biote Corp. has a 12-month low of $3.04 and a 12-month high of $8.44. The company has a market cap of $218.29 million, a PE ratio of 15.35 and a beta of 1.17. The stock has a 50 day simple moving average of $3.61 and a 200-day simple moving average of $4.93.

biote (NASDAQ:BTMD) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $48.99 million during the quarter, compared to analysts’ expectations of $47.25 million. biote had a negative return on equity of 32.41% and a net margin of 5.20%. Sell-side analysts forecast that biote Corp. will post 0.75 earnings per share for the current fiscal year.

Institutional Trading of biote

A number of institutional investors have recently made changes to their positions in BTMD. Kanen Wealth Management LLC bought a new stake in biote during the fourth quarter worth approximately $1,791,000. Hillsdale Investment Management Inc. acquired a new stake in shares of biote in the fourth quarter valued at $1,561,000. Marshall Wace LLP acquired a new position in biote during the fourth quarter worth about $543,000. Trexquant Investment LP raised its position in biote by 423.1% in the fourth quarter. Trexquant Investment LP now owns 101,757 shares of the company’s stock worth $629,000 after acquiring an additional 82,303 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in biote in the 4th quarter valued at about $445,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Craig Hallum cut their price objective on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.